Edition:
India

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

271.20CHF
24 May 2019
Change (% chg)

CHF1.70 (+0.63%)
Prev Close
CHF269.50
Open
CHF269.00
Day's High
CHF273.35
Day's Low
CHF269.00
Volume
924,128
Avg. Vol
1,661,117
52-wk High
CHF280.55
52-wk Low
CHF206.35

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.94
Market Cap(Mil.): CHF233,895.00
Shares Outstanding(Mil.): 862.56
Dividend: 8.70
Yield (%): 3.06

Financials

  ROG.S Industry Sector
P/E (TTM): 22.28 31.17 35.48
EPS (TTM): 12.17 -- --
ROI: 20.69 12.05 11.75
ROE: 38.71 13.36 16.52

Roche sees no Brexit interruption for patients

ZURICH, April 17 Roche holding ag ceo says sales growth for hemlibra primarily driven by non-inhibitors patients Roche holding ag ceo says spark therapeutics acquisition planned to be completed in first half Roche holding ag ceo says still believes biosimilars will enter market in u.s. In second half Roche holding ag says sees continued "very strong" growth for ocrevus after entry of novartis's mayzent Roche holding ag drugs chief says gantenerumab for alzheimers remains a high risk

17 Apr 2019

Roche says $4.3 billion Spark offer still on track for June completion

ZURICH Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

03 Apr 2019

Roche says $4.3 billion Spark offer still on track for June completion

ZURICH Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

03 Apr 2019

UPDATE 1-Roche extends Spark offer after getting only 29 pct

ZURICH, April 3 Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting only 29.4 percent of Spark's shares in a tender originally due to end on Wednesday.

03 Apr 2019

Roche extends Spark offer after getting 29 pct in tender

ZURICH, April 3 Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting 29.4 percent of Spark's shares in a tender originally due to end on Wednesday.

03 Apr 2019

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

19 Mar 2019

Lilly's combo therapy succeeds in late-stage lung cancer study

Eli Lilly and Co's combination cancer treatment met the main goal of a late-stage clinical trial testing it on patients with a form of lung cancer, the drugmaker announced on Tuesday.

12 Mar 2019

Lilly's combo treatment meets main goal in lung cancer late-stage study

March 12 Eli Lilly and Co said on Tuesday that its combo treatment, Cyramza, met the main goal in a late-stage study in patients with a form of lung cancer.

12 Mar 2019

Wall Street rises after Trump stirs China trade hopes again

NEW YORK Wall Street's three major indexes ended higher on Monday but well below the session's highs after President Donald Trump said he would delay a planned hike in tariffs on Chinese imports. | Video

26 Feb 2019

Wall Street rises after Trump stirs China trade hopes again

NEW YORK Wall Street's three major indexes ended higher on Monday but well below the session's highs after President Donald Trump said he would delay a planned hike in tariffs on Chinese imports. | Video

26 Feb 2019

Earnings vs. Estimates